An important scientific goal in attempting to address the problem of cocaine abuse is to gain a fuller understanding of the neural basis for the behavioral effects of cocaine that are relevant to its abuse. This project proposes to approach this question by examining the hypothesis that cocaine acts by binding to a site on the dopamine uptake transporter, increasing dopaminergic activation in critical brain regions leading to the production of psychomotor activation and cocaine-like intoxication and reinforcement. If this hypothesis is true, then other drugs which share these biochemical actions with cocaine should produce cocaine-like behavioral and pharmacological effects. Studies of biochemical and behavioral actions of cocaine and various cocaine analogues on measures relevant to this hypothesis are proposed to be carried out in rats. The methods to be employed are in vitro and in vivo binding to the cocaine site, quantitative autoradiographic determination of binding distribution, in vitro dopamine uptake, in vivo measurements of dopaminergic activation as revealed by increased metabolism and changes in extracellular dopamine concentrations as measured using microdialysis, the acoustic startle reflex to measure psychomotor activation, and drug discrimination as a model of cocaine-like subjective effects. Some of these methods will also provide information on drug effects on neurotransmitter systems other than the dopamine system. This will help determine how biochemical specificity of action alters the in vivo biochemical and behavioral expression of cocaine-like effects. Drugs to be tested include a) structural analogues of cocaine where the results can be related to other structure-activity and molecular modeling studies underway by our collaborator. When completed these studies will provide information on the precise structural requirements for actions at the cocaine site and on whether analogues may be found that bind to the site but lack a full-spectrum of cocaine-like effects. b) Other drugs structurally unrelated to cocaine that bind to the cocaine site will be evaluated for their profile of pharmacological effects. c) Finally, selected local anesthetics, which bind to the cocaine site and share some of the behavioral effects of cocaine, will also be tested. These studies will help determine if binding to the cocaine site on the dopamine transporter is sufficient to predict cocaine-like pharmacological effects and should lead to the identification of drugs that will share some but not all of the actions of cocaine and thus may be useful probes for further study of the neuropharmacology of cocaine and may modify the effects of cocaine in the therapeutically useful way.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005274-08
Application #
3731945
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Bagdas, Deniz; Alkhlaif, Yasmin; Jackson, Asti et al. (2018) New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 138:72-79
Jackson, Kia J; Muldoon, Pretal P; Walters, Carrie et al. (2016) Neuronal calcium/calmodulin-dependent protein kinase II mediates nicotine reward in the conditioned place preference test in mice. Behav Pharmacol 27:50-6
Nass, Sara R; Long, Jonathan Z; Schlosburg, Joel E et al. (2015) Endocannabinoid Catabolic Enzymes Play Differential Roles in Thermal Homeostasis in Response to Environmental or Immune Challenge. J Neuroimmune Pharmacol 10:364-70
Muldoon, P P; Chen, J; Harenza, J L et al. (2015) Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol 172:869-82
Poklis, Justin L; Devers, Kelly G; Arbefeville, Elise F et al. (2014) Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:e14-20
Poklis, Justin L; Nanco, Carol R; Troendle, Michelle M et al. (2014) Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 6:764-9
Ignatowska-Jankowska, B M; Ghosh, S; Crowe, M S et al. (2014) In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects. Br J Pharmacol 171:1392-407
Bagdas, Deniz; Muldoon, Pretal P; Zhu, Andy Z X et al. (2014) Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology 85:67-72
Wolf, Carl E; Goldstein, Ashley; Poklis, Justin L et al. (2014) Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine. J Clin Lab Anal 28:136-40
Burston, James J; Sagar, Devi Rani; Shao, Pin et al. (2013) Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint. PLoS One 8:e80440

Showing the most recent 10 out of 106 publications